SCHEMBL20818851

SCHEMBL20818851

CC(C)(C)OC(=O)N1C2CC1CN(c1cn[nH]c(=O)c1Br)C2

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TRPC5 Q9UL62 8/20 0.42
▸ JAK1 P23458 2/20 0.40
▸ SPR P35270 1/20 0.40
▸ CHRM2 P08172 1/20 0.39
▸ CHRM1 P11229 1/20 0.39
▸ CHRM3 P20309 1/20 0.39
▸ GPR119 Q8TDV5 1/20 0.38
▸ TIPARP Q7Z3E1 2/20 0.37
▸ RET P07949 2/20 0.37
▸ NR1H2 P55055 1/20 0.35
▸ IDO1 P14902 1/20 0.35
▸ TDO2 P48775 1/20 0.35
▸ PSEN1 P49768 1/20 0.35
▸ PSEN2 P49810 1/20 0.35
▸ APH1B Q8WW43 1/20 0.35
▸ NCSTN Q92542 1/20 0.35
▸ APH1A Q96BI3 1/20 0.35
▸ PSENEN Q9NZ42 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25230738 0.82 TRPC5 (0.46) TRPC5TIPARP
SCHEMBL20817915 0.80 TRPC5 (0.50) TRPC5GPR119NR1H2
SCHEMBL20831929 0.78 TRPC5 (0.46) TRPC5SPRGPR119IDO1TDO2
SCHEMBL20818796 0.78 PSEN1 (0.43) TRPC5SPRGPR119RETNR1H2
SCHEMBL20818174 0.76 NR1H2 (0.46) TRPC5GPR119TIPARPNR1H2
SCHEMBL24762523 0.76 JAK1 (0.41) JAK1SPRCHRM2CHRM1CHRM3
SCHEMBL30877449 0.74 GPR119 (0.53) CHRM2CHRM1CHRM3GPR119RET
SCHEMBL30476346 0.74 TRPC5 (0.51) TRPC5SPRGPR119IDO1TDO2
SCHEMBL20832042 0.74 TRPC5 (0.51) TRPC5SPRGPR119IDO1TDO2
SCHEMBL23490014 0.73 PIM1 (0.50) TRPC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435078-B2 Pyridazinones and methods of use thereof GFB (ABC), LLC (US) 2025-10-07 — — US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 — — US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 — — US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 — — US disclosed
EP-3684364-A2 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2020-07-29 — — EP disclosed
WO-2019055966-A2 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2019-03-21 — — WO disclosed
WO-2019055966-A2 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2019-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF PDXK, ATP6V1B1, REN TRPC5 1439/4885JAK1 3073/4885SPR 3274/4885
US-12435078-B2 Pyridazinones and methods of use thereof PDXK, ATP6V1B1, REN TRPC5 1439/4885JAK1 3073/4885SPR 3274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback